Iovance Biotherapeutics Inc (IOVA)

May 14, 2025, 10:00 AM EDT - 3 hours ago

Iovance Biotherapeutics, Inc. (IOVA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 13, 2025, 10:00 AM EDT - 1 day ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Iovance Biotherapeutics, Inc. (IOVA) and Encourages Stockholders to Learn More About the Investigation

May 13, 2025, 9:00 AM EDT - 1 day ago

Iovance Biotherapeutics' (IOVA) Annual Maintenance: Assurances Collide with Adverse Disclosure as Shares Plunge 44% - Hagens Berman

May 12, 2025, 4:00 PM EDT - 1 day ago

Bronstein, Gewirtz & Grossman, LLC Encourages Iovance Biotherapeutics, Inc. (IOVA) Investors to Inquire about Securities Investigation

May 12, 2025, 8:40 AM EDT - 2 days ago

Iovance Biotherapeutics' (IOVA) Annual Maintenance: Assurances Collide with Adverse Disclosure as Shares Plunge 44% – Hagens Berman

May 12, 2025, 1:28 AM EDT - 2 days ago

Iovance Biotherapeutics: Abysmal Q1 2025 Performance Creates Buying Opportunity

May 9, 2025, 11:33 AM EDT - 5 days ago

Iovance Stock Sinks 46%. Here's Why the Biotech Is Tumbling.

May 9, 2025, 9:38 AM EDT - 5 days ago

No Excuses, Iovance Biotherapeutics' Amtagvi Launch Has Underperformed

May 8, 2025, 10:01 PM EDT - 5 days ago

Iovance Biotherapeutics, Inc. (IOVA) Q1 2025 Earnings Call Transcript

May 2, 2025, 4:01 PM EDT - 11 days ago

Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025

Apr 23, 2025, 4:15 PM EDT - 20 days ago

Iovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses

Apr 18, 2025, 5:30 PM EDT - 25 days ago

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Mar 26, 2025, 7:06 AM EDT - 7 weeks ago

Top 3 Health Care Stocks That Are Set To Fly This Month

ARVN SLP

Feb 28, 2025, 1:01 PM EST - 2 months ago

Iovance's Q4: Execution Risks Mount As Infusion Growth Slows (Rating Downgrade)

Feb 27, 2025, 9:12 PM EST - 2 months ago

Iovance Biotherapeutics, Inc. (IOVA) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:01 PM EST - 2 months ago

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024

Feb 18, 2025, 4:01 PM EST - 3 months ago

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025

Feb 10, 2025, 7:00 AM EST - 3 months ago

Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer

Jan 13, 2025, 6:10 PM EST - 4 months ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

Jan 8, 2025, 11:13 AM EST - 4 months ago

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

AMGN BBIO BMY LLY MDGL MRK PFE

Nov 26, 2024, 4:01 PM EST - 6 months ago

Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer

Nov 11, 2024, 2:16 PM EST - 6 months ago

Iovance Biotherapeutics Q3: A Beat, But A Selloff - Now A Buy Opportunity

Nov 7, 2024, 8:55 PM EST - 6 months ago

Iovance Biotherapeutics, Inc. (IOVA) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:01 PM EST - 6 months ago

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024

Oct 31, 2024, 4:01 PM EDT - 6 months ago

Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024

Oct 3, 2024, 2:43 PM EDT - 7 months ago

Iovance Biotherapeutics: Moving To The Next Phase

Sep 3, 2024, 5:00 PM EDT - 9 months ago

Iovance Biotherapeutics to Present at Upcoming Conferences

Aug 11, 2024, 9:00 AM EDT - 9 months ago

Iovance's Tumor-Fighting TILs Are Just Warming Up (Rating Upgrade)

Aug 9, 2024, 11:20 AM EDT - 9 months ago

Skin Cancer-Focused Iovance Biotherapeutics Reports Better-Than-Expected 2024, 2025 Outlook, Stock Surges

Aug 8, 2024, 8:32 PM EDT - 9 months ago

Iovance Biotherapeutics, Inc. (IOVA) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:01 PM EDT - 9 months ago

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024

Jul 29, 2024, 4:01 PM EDT - 10 months ago

Iovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024

Jul 29, 2024, 1:55 PM EDT - 10 months ago

Iovance Biotherapeutics Price Forecast Slashed By 40% On Mutated Uptake For Its Newly Approved Skin Cancer Cell Therapy

Jun 28, 2024, 7:00 AM EDT - 11 months ago

Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma

May 24, 2024, 4:01 PM EDT - 1 year ago

Iovance Biotherapeutics to Present at Upcoming Conferences and Events

May 23, 2024, 5:00 PM EDT - 1 year ago

Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting

May 9, 2024, 8:40 PM EDT - 1 year ago

Iovance Biotherapeutics, Inc. (IOVA) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:01 PM EDT - 1 year ago

Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

May 6, 2024, 9:28 AM EDT - 1 year ago

Iovance (IOVA) stock price could jump by 30% after earnings

May 1, 2024, 6:01 AM EDT - 1 year ago

Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024

Apr 24, 2024, 4:01 PM EDT - 1 year ago

Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting

Apr 9, 2024, 6:05 AM EDT - 1 year ago

Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results

Mar 24, 2024, 11:25 PM EDT - 1 year ago

Rise Of The Rest, Look Past Mega Caps, And Invest Elsewhere

AAPL AER AMZN BA BDTX DFH DHI

Mar 4, 2024, 6:30 AM EST - 1 year ago

Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer